Next Article in Journal
Diffusion-Weighted MRI—The Way Forward for MRI in Myeloma?
Next Article in Special Issue
Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. Gösta Gahrton
Previous Article in Journal
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
Previous Article in Special Issue
Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect

Current Status of CAR-T Cell Therapy in Multiple Myeloma

Department of Hematology, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University Hospital Virgen del Rocio, Universidad de Sevilla, 41013 Sevilla, Spain
Author to whom correspondence should be addressed.
Academic Editors: Nicolaus Kröger and Laurent Garderet
Hemato 2021, 2(4), 660-671;
Received: 30 July 2021 / Revised: 8 October 2021 / Accepted: 18 October 2021 / Published: 21 October 2021
Current data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, current trials report an overall response rate ranging from 81 to 97% and 45 to 67% of complete remission rates. Data are less encouraging in terms of duration of response, although most recent trials have shown significant improvements in terms of event-free survival, with medians ranging from 8 to 14 months and up to 77% progression-free survival at 12 months with an acceptable toxicity profile. These data will be consolidated in future years and will provide new evidence on the best timing for CAR-T cell therapy. Moreover, new CAR-T designs are underway and will challenge the current results. View Full-Text
Keywords: myeloma; CAR T-cells; target antigen myeloma; CAR T-cells; target antigen
MDPI and ACS Style

Reguera-Ortega, J.L.; García-Guerrero, E.; Pérez-Simón, J.A. Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato 2021, 2, 660-671.

AMA Style

Reguera-Ortega JL, García-Guerrero E, Pérez-Simón JA. Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato. 2021; 2(4):660-671.

Chicago/Turabian Style

Reguera-Ortega, Juan Luis, Estefanía García-Guerrero, and Jose Antonio Pérez-Simón. 2021. "Current Status of CAR-T Cell Therapy in Multiple Myeloma" Hemato 2, no. 4: 660-671.

Find Other Styles

Article Access Map by Country/Region

Back to TopTop